Pathalys Pharma, Inc. develops therapeutics for the management of chronic kidney disease (CKD).

Pathalys

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD). Pathalys was created in partnership with Catalys Pacific and DaVita to become a multi-asset pharmaceutical company focused on the needs of patients with end-stage renal disease.

Catalys Pacific

DaVita Venture Group

Abingworth

OrbiMed

The Carlyle Group

Pathalys Pharma

Pathalys Pharma Secures $105 Million Series B Financing - https://bit.ly/4fUovtu #Innovation #kidneydisease #finance

Viewport Meta

IPhone / Mobile Compatible

Apple Mobile Web Clips Icon

Google Font API

WordPress

Amazon

Font Awesome

reCAPTCHA

GStatic Google Static Content

Amazon Virginia Region

Business Management

Neal Fowler

Chief Medical Officer and SrVP Clinical Development

Theodore. Danoff

Senior Vice President, Technical Operations

David Banks

Finance and Administration

Greg Klatt

Roger Zhang

Mahesh Krishnan

Co-Founder

Jay P. Shepard

Bastian Dehmel

Takeshi Takahashi

Ashwin Ram

BT Slingsby

Co-Founder and Executive Chairman

Southern US Startups Founded in 2021

North Carolina Companies With Fewer Than 1000 Employees (Top 10K)

United States Companies With Fewer Than 50 Employees (Top 10K)

Corporate VC Funded Companies (Top 10K)

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).

TCG Crossover

Series B - Pathalys Pharma

Series A - Pathalys Pharma

Debt Financing - Pathalys Pharma

Seed Round - Pathalys Pharma

Raleigh

North Carolina

United States

North America

Swing States Are Also In The Middle For Startup Funding

The Week’s 10 Biggest Funding Rounds: Grafana Labs Raises $270M To Lead Slow Week

Pathalys Pharma Secures $105 Million Series B Financing

Pathalys Pharma Appoints Dr. Bastian Dehmel as Chief Medical Officer

North Carolina’s Research Triangle Could See A Boost From SVB Deal

The 10 Biggest Rounds Of January: OpenAI Starts Out The Year With A Big Bang

The Week’s 10 Biggest Funding Rounds: Pathalys Pahrama Lands $150M; Impel Drives Away With $104M

Pathalys Pharma Raises $150M

An investigational calcimimetic for treating secondary hyperparathyroidism in patients undergoing hemodialysis. Delivered intravenously, it aims to control parathyroid hormone levels.

Clinical trials designed to evaluate the efficacy of Upacicalcet in reducing parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

Pakistan

Asia

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 21, 2024 9:21 AM	8538c8a9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	b8ff538b
crunchbase profile	general	Nov 25, 2024 9:30 AM	3f761576
li profile	general	Aug 21, 2024 9:21 AM	8544d293
translate crunchbase fundingrounds	general	Nov 25, 2024 2:28 PM	aaa1faa5
peers	general	Aug 21, 2024 9:21 AM	cc4b0ccf
news basic	general	Aug 21, 2024 9:21 AM	7237d3c9
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PATHALYS

Pathalys